{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=11",
    "query": {
      "intervention": "Control label",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 3333,
    "total_pages": 334,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+label&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T11:32:24.970Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06101095",
      "title": "A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Eosinophilic Oesophagitis"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2023-11-29",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 15,
      "location_summary": "Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06101095"
    },
    {
      "nct_id": "NCT01895777",
      "title": "Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate",
          "type": "DRUG"
        },
        {
          "name": "standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 267,
      "start_date": "2013-09-25",
      "completion_date": "2019-11-14",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Miami, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01895777"
    },
    {
      "nct_id": "NCT06344416",
      "title": "Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Any Solid Oral Medication"
      ],
      "interventions": [
        {
          "name": "Use of ReX to dispense and monitor solid oral medication therapy.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Dosentrx Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-03-30",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 4,
      "location_summary": "Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06344416"
    },
    {
      "nct_id": "NCT05184335",
      "title": "Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Brilaroxazine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Reviva Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 690,
      "start_date": "2022-01-24",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 18,
      "location_summary": "Phoenix, Arizona • Bentonville, Arkansas • Little Rock, Arkansas + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05184335"
    },
    {
      "nct_id": "NCT06236113",
      "title": "Low Dose Ketamine for Blunt Thoracic Trauma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Blunt Injury of Thorax",
        "Multiple Rib Fractures, Involving Three Ribs"
      ],
      "interventions": [
        {
          "name": "Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "North Memorial Health Care",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2021-10-01",
      "completion_date": "2023-06-26",
      "has_results": true,
      "last_update_posted_date": "2024-05-21",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 1,
      "location_summary": "Robbinsdale, Minnesota",
      "locations": [
        {
          "city": "Robbinsdale",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06236113"
    },
    {
      "nct_id": "NCT02363426",
      "title": "Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infertility"
      ],
      "interventions": [
        {
          "name": "INVOcell Culture Device",
          "type": "DEVICE"
        },
        {
          "name": "IVF Incubation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Invaron Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "38 Years",
        "sex": "ALL",
        "summary": "18 Years to 38 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-01",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 1,
      "location_summary": "Beford, Texas",
      "locations": [
        {
          "city": "Beford",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02363426"
    },
    {
      "nct_id": "NCT01743625",
      "title": "Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain, Postoperative",
        "Bunion"
      ],
      "interventions": [
        {
          "name": "COV155",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mallinckrodt",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 406,
      "start_date": "2012-11",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2016-10-19",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 5,
      "location_summary": "Anaheim, California • Pasadena, California • Pasadena, Maryland + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01743625"
    },
    {
      "nct_id": "NCT01265576",
      "title": "Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HCC"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "VT-122 (propranolol plus etodolac)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2010-12",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2015-12-09",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 10,
      "location_summary": "Berkeley, California • Atlanta, Georgia • New Brunswick, New Jersey + 6 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01265576"
    },
    {
      "nct_id": "NCT06686017",
      "title": "Virtuos Bone Graft in Lumbar Fusion",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Degenerative Disc Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Orthofix Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-06-05",
      "completion_date": "2029-04",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 9,
      "location_summary": "South Bend, Indiana • Southfield, Michigan • Missoula, Montana + 5 more",
      "locations": [
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Southfield",
          "state": "Michigan"
        },
        {
          "city": "Missoula",
          "state": "Montana"
        },
        {
          "city": "Pinehurst",
          "state": "North Carolina"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686017"
    },
    {
      "nct_id": "NCT00499655",
      "title": "Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2007-11",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-10-21T11:32:24.970Z",
      "location_count": 2,
      "location_summary": "Duarte, California • South Pasadena, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499655"
    }
  ]
}